Clinical trials: Antibody
Multiple Myeloma, Plasma Cell Myeloma
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00064337
- Testing
- filgrastim, cyclophosphamide, dexamethasone
- Where
- 35 sites in United States
- Volunteers
- 104 people
- Sponsor
- SWOG Cancer Research Network
Atopic Dermatitis, Immunoglobulin E Concentration, Serum
The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy
Extrinsic - atopic dermatitis is characterized by increased of IgE serum levels. Acute extrinsic - atopic dermatitis is a type 1 hypersensitivity that involve various inflammatory mediator including Interleukin-4, Interleukin-12…
- Trial name
- NCT04018131
- Testing
- Cimetidine
- Where
- Indonesia
- Volunteers
- 26 people
- Sponsor
- Fakultas Kedokteran Universitas Indonesia
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00084656
- Testing
- ipilimumab, Tyrosinase/gp100/MART-1 Peptides
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Based on pilot patient observations, and experience from the prior study KTS-1-2008, the investigators anticipate that severely affected chronic fatigue syndrome patients may benefit from B-cell depletion therapy using Rituximab…
- Trial name
- NCT01156922
- Testing
- Rituximab
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Haukeland University Hospital
HIV-1-infection
Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens
The objective of this experimental medicine study is to determine the extent to which different prime-boost combinations influence serum neutralising antibody breadth and associated B and T cells responses.
- Trial name
- EAVI2020_01 (NCT03816137)
- Testing
- ConM SOSIP, EDC ConM SOSIP, ConS UFO
- Where
- United Kingdom
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Advanced Solid Tumors
A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.
- Trial name
- NCT03787953
- Testing
- Anti-PD-1/PD-L1 antibodies
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma and Plasma Cell Neoplasm
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients…
- Trial name
- NCT00003853
- Testing
- 4'-iodo-4'-deoxydoxorubicin
- Where
- 3 sites in United States, Italy
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00311545
- Testing
- CNTO 328
- Sponsor
- SWOG Cancer Research Network
Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic…
- Trial name
- PROBE (NCT07825753)
- Testing
- Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Fudan University
Ovarian Cancer
Blood Test for Ovarian Cancer Associated Auto Antibodies
Intend of use: A blood test for Cancer Associated Antibodies (CAAA) is an aid in initial diagnosis of ovarian cancer in women with suspected ovarian pathology as detected by primary diagnostic techniques.
- Trial name
- NCT01334437
- Where
- Israel
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Eventus Diagnostics Ltd
Bile Duct Obstruction, Extrahepatic
Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct Cancer
The sensitivity of brushing cytology used to distinguish the cause of biliary strictures is low and clinical usefulness is not secured.
- Trial name
- NCT03708445
- Testing
- Cytology staining
- Where
- 6 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Gangnam Severance Hospital
Primary Immunodeficiency
IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
Most immunodeficiencies are related to severe immunoglobulin deficiencies which require lifelong replacement therapy with immunoglobulin G (IgG) to reduce the incidence and severity of infections.
- Trial name
- NCT02881437
- Testing
- IgHy10
- Where
- 7 sites in France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Lille
Solid Tumors
A Study of ERY974 in Patient With Advanced Solid Tumors
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity.
- Trial name
- NCT02748837
- Testing
- ERY974
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- Chugai Pharmaceutical
Neuroblastoma
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
The purpose of this study is to compare the pharmacokinetics (blood levels) and safety of chimeric (ch) 14.18 manufactured by two independent drug makers (United Therapeutics [UTC] or the National Cancer Institute [NCI]).
- Trial name
- NCT01592045
- Testing
- ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- United Therapeutics
Early Low Rectal Cancer
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
TORCH-E2 is a prospective, multicentre, randomized phase II trial. 134 low-lying early (T1-3b/N0-1M0, distance from anal verge ≤5cm) patients will be recruited and assigned to Group 1 and Group 2 (1:1).
- Trial name
- TORCH-E2 (NCT06462053)
- Testing
- Short-course radiotherapy, PD-1 antibody (Toripalimab), Long-course radiotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Fudan University
COVID-19
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 \& SCTA01C compared to placebo in addition to Standard of…
- Trial name
- NCT05156645
- Testing
- SCTA01 and SCTA01C
- Sponsor
- Sinocelltech Ltd.
Antiphospholipid Syndrome
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
The antiphospholipid-antibody syndrome (APLA), which includes lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoproteinI antibodies, is a thrombophilic disorder associated with arterial thrombosis, venous thrombosis or…
- Trial name
- NCT00878137
- Testing
- INR by point-of-care instruments and venopuncture
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of North Carolina, Chapel Hill
Covid-19
Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices.
- Trial name
- YCOVID (NCT04490837)
- Testing
- ELISA and Rapid test to detect antibodies against COVID-19
- Where
- Spain
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
Advanced Solid Tumor, Advanced Breast Cancer
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
- Trial name
- NCT05076591
- Testing
- IMM2902
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NSCLC, Chemotherapy
Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs
Research objective Main purpose Exploring the real-world effectiveness of Ivonescimab combined with chemotherapy for EGFR mutant NSCLC with leptomeningeal metastasis after EGFR-TKIs resistance.
- Conditions
- NSCLC, Chemotherapy, Leptomeningeal Metastases, EGFR-TKI
- Trial name
- NCT06766591
- Testing
- Ivonescimab combined with chemotherapy
- Volunteers
- 36 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.